Please assess the completion status of the following clinical trial:

Trial Title: Misoprostol Administration Before Operative Hysteroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Symptomatic patients that were suspected as having intrauterine pathology, such as submucosal myoma, endometrial polyp or other endometrial pathological findings based on the transvaginal ultrasound, were enrolled.~Inclusion criteria were as follows: women who were of reproductive age (i.e., were premenopausal) and were not pregnant at the time of presentation (i.e., negative for urine pregnancy test or last menstrual period within the last 4 weeks). -~Exclusion Criteria:~Exclusion criteria included any evidence of a contraindication to prostaglandins (history of severe asthma, glaucoma, preexisting severe cardiac disease, or renal failure), or allergy to prostaglandins, any sign of genital infection, presence of significant uterovaginal prolapse that could affect administration of vaginal tablets, history of cervical surgery, presence of space occupying lesions in endocervical canal, and treatment of GnRH agonist.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Oral misoprostol (Type: EXPERIMENTAL): The oral group (misoprostol 400 ug) self-administered the medications orally 8-10 h before surgery.
- Sublingual misoprostol (Type: EXPERIMENTAL): The sublingual group (misoprostol 400 ug) self-administered the medications sublingually 8-10 h before surgery.
- Vaginal misoprostol (Type: EXPERIMENTAL): The vaginal group (misoprostol 400 ug) self-administered the medications vaginally 8-10 h before surgery.
- Control (Type: EXPERIMENTAL): The no-misoprostol group did not administer the medication of misoprostol before the procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).